Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

SB 207499

Known as: SB-207499 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cilomilast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast
Phosphodiesterase-4 (PDE4) is an important cAMP-metabolising enzyme in immune and inflammatory cells, airway smooth muscle and… Expand
Review
2006
Review
2006
[Current and future approaches for the treatment of inflammatory diseases of inferior respiratory tract].
Among the allergic disorders we emphasize the inflammatory diseases of the inferior respiratory tract by their incidence… Expand
Highly Cited
2002
Highly Cited
2002
Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor…
In an attempt to elaborate in vitro on a therapeutic strategy that counteracts an inflammatory signal, we previously reported a… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
2002
2002
In vitro PKA phosphorylation‐mediated human PDE4A4 activation
The PDE4 catalytic machinery comprises, in part, two divalent cations in a binuclear motif. Here we report that PDE4A4 expressed… Expand
2002
2002
Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… Expand
Review
2001
Review
2001
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
  • M. Giembycz
  • Expert opinion on investigational drugs
  • 2001
    • Corpus ID: 21654297
Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective… Expand
Highly Cited
2000
Highly Cited
2000
Conformational difference between PDE4 apoenzyme and holoenzyme.
The type 4 cAMP-specific phosphodiesterases (PDE4s) are Mg(2+)-dependent hydrolases that catalyze the hydrolysis of 3', 5'-cAMP… Expand
2000
2000
PDE inhibitors--Second William Harvey Research Conference. Drugs with an expanding range of therapeutic uses. 1-3 December 1999, Nice, France.
  • T. Torphy
  • IDrugs : the investigational drugs journal
  • 2000
    • Corpus ID: 30380859
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One… Expand
Review
1999
Review
1999
Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases.
Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease… Expand
Highly Cited
1998
Highly Cited
1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.
We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE